Skip to main content
Clinical Trials/ACTRN12622000506796
ACTRN12622000506796
Completed
未知

ong-term outcomes of myocarditis and pericarditis after Pfizer-BioNTech (Comirnaty) COVID-19 vaccination in children and adults

Medsafe0 sites323 target enrollmentMarch 30, 2022

Overview

Phase
未知
Intervention
Not specified
Conditions
Not specified
Sponsor
Medsafe
Enrollment
323
Status
Completed
Last Updated
3 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
March 30, 2022
End Date
October 10, 2022
Last Updated
3 years ago
Study Type
Observational
Sex
All

Investigators

Sponsor
Medsafe

Eligibility Criteria

Inclusion Criteria

  • 1\) Adults and children 12 years of age or older with a clinical diagnosis of myocarditis and/or pericarditis (includes myopericarditis), after any dose of the Pfizer vaccine, and their healthcare providers.
  • 2\) A report of myocarditis and/or pericarditis has been submitted to the Centre for Adverse Reactions Monitoring (CARM) by the person themselves, or by someone on their behalf (such as a healthcare professional or family member).
  • 3\) Participants will not be required to meet specific diagnostic criteria, such as the CDC criteria, to be eligible.
  • 4\) Myocarditis and/or pericarditis diagnosed up to and including 28 February 2022, and at least 3 months prior to the survey (minimum of 3 months post\-diagnosis).

Exclusion Criteria

  • 1\) Children \<12 years of age.
  • 2\) People who have not received a clinical diagnosis of myocarditis and/or pericarditis. This includes self\-diagnosis, or where a diagnosis of myocarditis or pericarditis was considered as part of the differential diagnosis but was not given as a final diagnosis.
  • 3\) Myocarditis and/or pericarditis diagnosed after 28 February 2022, and/or less than 3 months ago by the end of the specified recruitment period.
  • 4\) People who experienced myocarditis and/or pericarditis after a third or subsequent dose of the Pfizer vaccine.
  • 5\) People who did not receive the Pfizer vaccine prior to being diagnosed with myocarditis or pericarditis.
  • 6\) People who experienced myocarditis and/or pericarditis after vaccination with another COVID\-19 vaccine (for example, the AstraZeneca vaccine).
  • 7\) People who have not provided sufficient contact information in CARM report to be able to make initial contact.
  • 8\) Circumstances that interfere with the participant’s ability to give informed consent (including a diminished understanding or comprehension of English and an interpreter unavailable).

Outcomes

Primary Outcomes

Not specified

Similar Trials